[go: up one dir, main page]

TR200002242T2 - 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları. - Google Patents

5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.

Info

Publication number
TR200002242T2
TR200002242T2 TR2000/02242T TR200002242T TR200002242T2 TR 200002242 T2 TR200002242 T2 TR 200002242T2 TR 2000/02242 T TR2000/02242 T TR 2000/02242T TR 200002242 T TR200002242 T TR 200002242T TR 200002242 T2 TR200002242 T2 TR 200002242T2
Authority
TR
Turkey
Prior art keywords
alpha
imidazolinylamino
preparation
adrenoceptor agonists
metabolic stability
Prior art date
Application number
TR2000/02242T
Other languages
English (en)
Inventor
Lee Cupps Thomas
Lee Bogdan Sophie
Nikolaides Nicholas
Ann Gilbert Sheri
Gazda Michael
Lee Martin Dobson Roy
Iii Charles Andrew Cruze
Original Assignee
The Procter &Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter &Gamble Company filed Critical The Procter &Gamble Company
Publication of TR200002242T2 publication Critical patent/TR200002242T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Söz konusu bulus primatlarda metabolizmaya karsi gelismis direnç sahibi bazi ikameli benzimidazol bilesiklerine mahsus bir bulustur. Söz konusu bilesikler alfa adrenoseptör agonistleridirler ve alfa agonist baglantili hastaliklarin tedavisinde faydalidirlar.
TR2000/02242T 1997-11-24 1998-11-20 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları. TR200002242T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US6670097P 1997-11-25 1997-11-25

Publications (1)

Publication Number Publication Date
TR200002242T2 true TR200002242T2 (tr) 2000-11-21

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02242T TR200002242T2 (tr) 1997-11-24 1998-11-20 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.

Country Status (23)

Country Link
US (1) US6486190B1 (tr)
EP (1) EP1037887B1 (tr)
JP (1) JP2001524478A (tr)
KR (1) KR20010032435A (tr)
CN (1) CN1284073A (tr)
AT (1) ATE271048T1 (tr)
BR (1) BR9815017A (tr)
CA (1) CA2311344C (tr)
CO (1) CO4970802A1 (tr)
DE (1) DE69825075T2 (tr)
ES (1) ES2223143T3 (tr)
HU (1) HUP0101469A3 (tr)
IL (1) IL136303A (tr)
IN (1) IN190809B (tr)
NO (1) NO20002655L (tr)
NZ (1) NZ504707A (tr)
PE (1) PE133699A1 (tr)
PL (1) PL340711A1 (tr)
RU (1) RU2193562C2 (tr)
SK (1) SK7792000A3 (tr)
TR (1) TR200002242T2 (tr)
TW (1) TW505642B (tr)
WO (1) WO1999026942A1 (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1385823T3 (da) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
RU2225401C1 (ru) * 2002-09-16 2004-03-10 Катаев Валерий Алексеевич 5(6)-нитро-1-(1,1-диоксотиетанил-3)-2-хлорбензимидазол, проявляющий биологическую активность
WO2004074234A1 (en) * 2003-02-20 2004-09-02 Lonza Ag Process for the preparation of n-substituted formamides
US20040167194A1 (en) 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
EP1761266B1 (en) * 2004-05-25 2013-05-08 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
RU2306137C1 (ru) * 2005-12-28 2007-09-20 Денис Вячеславович Лисицын Средство для профилактики и лечения гриппа
EP2819674A2 (en) * 2012-02-27 2015-01-07 Eye Therapies LLC Compositions and methods for the treatment of migraine
WO2015073736A1 (en) * 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
KR20180105129A (ko) * 2015-11-30 2018-09-27 노부스 테라퓨틱스, 인크. 이과학적 예방 및 치료를 위한 조성물 및 방법
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
DE3071229D1 (en) 1979-08-23 1985-12-19 Beecham Group Plc Anti-diarrhoea veterinary composition
US4436913A (en) 1980-09-05 1984-03-13 Siegfried Aktiengesellschaft 1H- and 2H- indazole derivatives
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
TW300219B (tr) * 1991-09-14 1997-03-11 Hoechst Ag
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
WO1996004270A1 (en) 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Novel benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
PL340711A1 (en) 2001-02-26
SK7792000A3 (en) 2001-01-18
WO1999026942A8 (en) 2000-08-03
JP2001524478A (ja) 2001-12-04
IN190809B (tr) 2003-08-23
EP1037887A1 (en) 2000-09-27
CO4970802A1 (es) 2000-11-07
ATE271048T1 (de) 2004-07-15
WO1999026942A1 (en) 1999-06-03
IL136303A0 (en) 2001-05-20
TW505642B (en) 2002-10-11
HUP0101469A2 (hu) 2001-10-28
KR20010032435A (ko) 2001-04-25
NO20002655D0 (no) 2000-05-24
BR9815017A (pt) 2001-09-11
CN1284073A (zh) 2001-02-14
DE69825075T2 (de) 2005-08-25
DE69825075D1 (de) 2004-08-19
NZ504707A (en) 2002-11-26
CA2311344C (en) 2006-02-07
US6486190B1 (en) 2002-11-26
RU2193562C2 (ru) 2002-11-27
IL136303A (en) 2004-02-08
CA2311344A1 (en) 1999-06-03
PE133699A1 (es) 2000-03-05
EP1037887B1 (en) 2004-07-14
HUP0101469A3 (en) 2003-01-28
NO20002655L (no) 2000-07-24
ES2223143T3 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
TR200002242T2 (tr) 5-(2-İmidazolinilamino)-benzimidazol türevleri, bunların hazırlanması ve metabolik kararlılığı gelişmiş alfa-adrenoseptör agonistleri olarak kullanımları.
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
TR200200588T2 (tr) N-pirazol A2A reseptör agonistleri
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
EP1482791A4 (en) ANTIMICROBIAL THERAPEUTIC COMPOSITIONS AND THEIR USE
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
ATE430743T1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
MX9303469A (es) Derivados de benzimidazol, procedimiento para su preparacion, composicion farmaceutica que los contiene y procedimiento para preparar de la misma.
MX2009010567A (es) Derivados de imidazolidinona.
BR0007864A (pt) Composto, e, uso de um composto
ECSP055793A (es) Forma de administración de ibuprofeno sódico
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
UY26226A1 (es) 'derivados de aminopirrolidina heterocíclica como agentes melatonergicos'.- ley 17.164.-
IS6426A (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
ES2181995T3 (es) Derivados de bencimidazol y uso como antagonistas del factor de liberacion de la corticotropina.
SE9904421D0 (sv) New compounds
DK2886D0 (da) Dopamin-beta-hydroxylaseinhibitorer
PE20021153A1 (es) 5-[2-BUTOXI-5-(1-HIDROXIETIL)-3-PIRIDINIL]-3-ETIL-2-(1-ETIL-3-AZETIDINIL)-2,6-DIHIDRO-7H-PIRAZOLO[4,3-d]PIRIMIDIN-7-ONA COMO INHIBIDORES DE FOSFODIESTERASAS DE GUANOSIN 3',5'-MONOFOSFATO CICLICO
TR199802033T2 (tr) Böcek öldürücü siprodinil ve miklobutanil bilesimi.
EA200100853A1 (ru) Резорциновая композиция
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
AR002749A1 (es) Derivados de estiril bencimidazol y composicion farmaceutica que los comprende.